Education
About Us
Working with TipRanks
Follow Us
Incyte Corp (INCY)
NASDAQ:INCY
INCY Stock Chart & Stats
$101.18
$0.53(0.72%)
At close: 4:00 PM EST
$101.18
$0.53(0.72%)
Day’s Range― - ―
52-Week Range$53.56 - $112.29
Previous CloseN/A
Volume384.35K
Average Volume (3M)1.80M
Market Cap
$19.86B
Enterprise Value$17.43B
Total Cash (Recent Filing)$2.93B
Total Debt (Recent Filing)$41.27M
Price to Earnings (P/E)17.0
Beta0.43
Next Earnings
Feb 10, 2026EPS Estimate
1.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.26
Shares Outstanding196,322,710
10 Day Avg. Volume1,582,102
30 Day Avg. Volume1,801,818
Financial Highlights & Ratios
PEG Ratio-4.67
Price to Book (P/B)4.15
Price to Sales (P/S)3.37
P/FCF Ratio57.43
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit3.94
Enterprise Value/Ebitda10.36
Forecast
1Y Price Target
$102.79Price Target Upside1.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Early Commercial Momentum For New LaunchesStrong early launch performance with solid patient retention for new products and plans to expand approved indications for a key dermatology drug into European markets could drive meaningful non‑flagship revenue growth.
Late‑stage Pipeline ProgressA concentrated late‑stage pipeline of several high‑value programs, including therapies targeting calreticulin and KRAS mutations, offers multiple upcoming clinical catalysts that could meaningfully replace legacy revenue.
Mutant CALR Clinical DataEncouraging mutant CALR clinical results showed improved anemia and a clean safety profile, supporting advancement to pivotal trials and suggesting a sizable commercial opportunity if outcomes remain favorable.
Bears Say
Limited Capital And Investor SkepticismLimited available capital for business development and skepticism from some investors about certain pipeline programs could constrain acquisitions and slow efforts to replace lost flagship revenue.
Loss Of Exclusivity RiskLoss of exclusivity for the flagship therapy is expected to create a material revenue shortfall that must be filled by other products to avoid prolonged sales declines.
Opzelura Commercial PressureDeclining tube usage for the dermatology product and uncertain commercial execution raise the risk that expected sales from this franchise may fall short of projections.
Incyte News
INCY FAQ
What was Incyte Corp’s price range in the past 12 months?
Incyte Corp lowest stock price was $53.56 and its highest was $112.29 in the past 12 months.
What is Incyte Corp’s market cap?
Incyte Corp’s market cap is $19.86B.
When is Incyte Corp’s upcoming earnings report date?
Incyte Corp’s upcoming earnings report date is Feb 10, 2026 which is in 11 days.
How were Incyte Corp’s earnings last quarter?
Incyte Corp released its earnings results on Oct 28, 2025. The company reported $2.26 earnings per share for the quarter, beating the consensus estimate of $1.606 by $0.654.
Is Incyte Corp overvalued?
According to Wall Street analysts Incyte Corp’s price is currently Undervalued.
Does Incyte Corp pay dividends?
Incyte Corp does not currently pay dividends.
What is Incyte Corp’s EPS estimate?
Incyte Corp’s EPS estimate is 1.91.
How many shares outstanding does Incyte Corp have?
Incyte Corp has 196,322,710 shares outstanding.
What happened to Incyte Corp’s price movement after its last earnings report?
Incyte Corp reported an EPS of $2.26 in its last earnings report, beating expectations of $1.606. Following the earnings report the stock price went down -1.536%.
Which hedge fund is a major shareholder of Incyte Corp?
Currently, no hedge funds are holding shares in INCY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Incyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$102.79 (1.59% Upside)
$102.79 (1.59% Upside)
Blogger Sentiment
Bullish
INCY Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 984.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $35.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 25.8%
Last 30 Days ▲ 25.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.31%
12-Months-Change
Fundamentals
Return on Equity
30.39%
Trailing 12-Months
Asset Growth
26.29%
Trailing 12-Months
Company Description
Incyte Corp
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
INCY Company Deck
INCY Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong financial performance and growth in key products like Jakafi and Opzelura. The launch of Niktimvo exceeded expectations. However, the decision to terminate certain programs due to regulatory and strategic priorities presented challenges. Overall, the sentiment was more positive given the revenue growth and successful product launches.View all INCY earnings summariesINCY Revenue Breakdown
85.33% Product revenues, net
13.66% Product royalty revenues
1.01% Milestone and contract revenues
INCY Stock 12 Month Forecast
Average Price Target
$102.79
▲(1.59% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---